| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.50.4.996 |
| P698 | PubMed publication ID | 9566385 |
| P50 | author | Marzia Baldereschi | Q43122653 |
| P2093 | author name string | Scarlato G | |
| Bracco L | |||
| Lepore V | |||
| Grigoletto F | |||
| Di Carlo A | |||
| Amaducci L | |||
| Maggi S | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Italy | Q38 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 996-1002 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. | |
| P478 | volume | 50 |
| Q27694738 | APP processing in Alzheimer's disease |
| Q33949774 | Aerodiol versus the transdermal route: perspectives for patient preference |
| Q34393812 | Alzheimer disease therapeutics |
| Q97887374 | Alzheimer's Disease, Inflammation, and the Role of Antioxidants |
| Q34174531 | Alzheimer's disease in man and transgenic mice: females at higher risk |
| Q47669564 | Alzheimer's disease: epidemiology |
| Q37315515 | Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause |
| Q34066474 | Antioxidant therapy in Alzheimer's disease: theory and practice |
| Q57318254 | Brain-Targeted Delivery of Estradiol |
| Q35955892 | Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. |
| Q78231381 | Cellular localization of estrogen receptors on neurones in various regions of cultured rat CNS: coexistence with cholinergic and galanin receptors |
| Q51983422 | Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. |
| Q37088621 | Cognitive changes after menopause: influence of estrogen |
| Q36443732 | Cognitive dysfunction with aging and the role of inflammation |
| Q30634935 | Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies |
| Q34777681 | Dementia epidemiology |
| Q36318129 | Diabetes, sugar-coated but harmful to the brain |
| Q35189725 | Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens |
| Q98204264 | Does parity matter in women's risk of dementia? A COSMIC collaboration cohort study |
| Q28071845 | Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's Disease |
| Q28547748 | Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study |
| Q44624452 | Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice |
| Q44018606 | Effects of hormone replacement therapy on olfactory sensitivity: cross-sectional and longitudinal studies |
| Q36134820 | Endocrinology of menopausal transition and its brain implications. |
| Q37085132 | Estradiol and neurodegenerative oxidative stress |
| Q40622571 | Estradiol prevents amyloid-beta peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor. |
| Q34767487 | Estrogen and Alzheimer's disease: the story so far. |
| Q35109605 | Estrogen and Cognitive Functioning in Women |
| Q28217161 | Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis |
| Q53270093 | Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. |
| Q42495290 | Estrogen replacement does not prevent the loss of choline acetyltransferase-positive cells in the basal forebrain following either neurochemical or mechanical lesions |
| Q46058009 | Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment |
| Q42523535 | Estrogen treatment suppresses forebrain p75 neurotrophin receptor expression in aged, noncycling female rats |
| Q34585797 | Estrogen, cognition and female ageing |
| Q37090625 | Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement |
| Q44303602 | Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study |
| Q35680612 | Hormone therapy and Alzheimer's disease: benefit or harm? |
| Q36528233 | Hypothalamic-pituitary-gonadal axis homeostasis predicts longevity |
| Q22250949 | Incidence of Dementia, Alzheimer's Disease, and Vascular Dementia in Italy. The ILSA Study |
| Q77462965 | Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease |
| Q43813758 | Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women |
| Q52027237 | Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. |
| Q37822795 | Menopause and mental well-being: timing of symptoms and timing of hormone treatment |
| Q43028519 | Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy |
| Q40006640 | Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. |
| Q34400504 | Neuroactive steroids and central nervous system disorders. |
| Q34395542 | Neuroimaging of aging and estrogen effects on central nervous system physiology |
| Q73515417 | Neuroprotective effects of chronic estradiol benzoate treatment on hippocampal cell loss induced by status epilepticus in the female rat |
| Q34991505 | Non-cholinergic strategies for treating and preventing Alzheimer's disease |
| Q37190255 | Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE {varepsilon}4 carriers: a case-control study. |
| Q40519882 | On the horizon: pathways for drug development in Alzheimer's disease |
| Q37244609 | Ovariectomy and 17beta-estradiol replacement do not alter beta-amyloid levels in sheep brain |
| Q34082306 | Part I. Epidemiology and public health impact of Alzheimer's disease |
| Q35957574 | Pharmacotherapeutic approaches to the prevention of Alzheimer's disease |
| Q34481842 | Pharmacotherapy in the treatment of Alzheimer's disease: an update |
| Q33516441 | Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). |
| Q37416371 | Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease |
| Q46562378 | Preliminary evidence that estrogen protects against age-related hippocampal atrophy |
| Q30708039 | Prevalence of dementia in users of hormone replacement therapy as defined by prescription data |
| Q48457507 | Progesterone reverses the spatial memory enhancements initiated by tonic and cyclic oestrogen therapy in middle-aged ovariectomized female rats |
| Q36436653 | Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. |
| Q88727192 | Rapid non-classical effects of steroids on the membrane receptor dynamics and downstream signaling in neurons |
| Q46044532 | Reactive astrocytes express estrogen receptors in the injured primate brain |
| Q33688768 | Recent developments in the drug treatment of Alzheimer's disease |
| Q33236269 | Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disea |
| Q73765058 | Self-rated health, life satisfaction and personal characteristics of post-menopausal women under estrogen replacement therapy |
| Q34240919 | Sex hormones and their impact on dementia and depression: a clinical perspective |
| Q36176965 | Sex, hormones, and Alzheimer's disease |
| Q48104189 | Sodium salicylate and 17beta-estradiol attenuate nuclear transcription factor NF-kappaB translocation in cultured rat astroglial cultures following exposure to amyloid A beta(1-40) and lipopolysaccharides |
| Q46667234 | Testosterone depletion increases the susceptibility of brain tissue to oxidative damage in a restraint stress mouse model |
| Q33507730 | The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers |
| Q38927944 | The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. |
| Q35444823 | The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease |
| Q34951934 | The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review |
| Q45557445 | The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes |
| Q45106144 | The implications of body fat mass and fat distribution for cognitive function in elderly women |
| Q35134604 | The menopause and HRT. HRT and cognitive decline |
| Q40735061 | The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. |
| Q33787542 | The prediction and prevention of Alzheimer's disease--towards a research agenda |
| Q37253034 | Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects |
| Q36528732 | Transdermal treatment options for neurological disorders: impact on the elderly |
| Q73118945 | Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain |
| Q37117105 | Use of transdermal drug formulations in the elderly |
| Q64989598 | [Alzheimer's disease: from pathology to preventive methods?]. |
Search more.